Clinical Movement

Tics & Tourette Syndrome

Tics & Tourette Syndrome

What Do You Need to Know?

  • Tics are sudden, rapid, recurrent, non-rhythmic movements or vocalizations preceded by a premonitory urge and are temporarily suppressible
  • Tourette syndrome: multiple motor tics + ≥1 vocal tic, onset <18 years, duration >1 year (DSM-5); male predominance 3–4:1. The most common initial tic is eye blinking (frequently tested board fact); motor tics typically precede vocal tics by 1–2 years.
  • Tics wax and wane in severity, type, and location over time — this fluctuation is characteristic
  • Comorbidities often more disabling than tics: ADHD (50–60%), OCD (40–60%), anxiety, depression
  • CBIT is first-line behavioral treatment; alpha-2 agonists (guanfacine, clonidine) first-line pharmacologic
  • Antipsychotics (fluphenazine, aripiprazole, pimozide) for severe/refractory tics — monitor QTc with pimozide
🚩 Don’t Miss — Test-Day Priorities
  • Tourette DSM-5: ≥2 motor tics + ≥1 vocal/phonic tic (need not be concurrent), duration >1 year, onset before age 18
  • Chronic (persistent) tic disorder: motor OR vocal tics (not both) >1 year; provisional tic disorder: <1 year duration
  • Premonitory urge preceding the tic + temporary voluntary suppressibility with rebound = hallmark distinguishing tics from other hyperkinetic movements
  • Tics wax and wane, worsen with stress/excitement/fatigue, improve with focused activity and sleep
  • Coprolalia is rare (~10–15%) and NOT required for diagnosis — common board trap; eye blinking is the most common initial tic
  • Comorbidities dominate the disease: ADHD ~50%, OCD ~50%, anxiety, depression, rage attacks — often more disabling than tics themselves; treat the most impairing condition first
  • PANDAS = abrupt prepubertal onset of OCD/tics after Group A strep (check ASO, anti-DNase B); PANS = broader non-strep triggers
  • Functional tic-like behaviors (rapid-onset adolescent females, COVID-era TikTok exposure surge): no premonitory urge, fixed/stereotyped, distractible, frequent complex coprolalia — do NOT respond to dopamine blockers
  • First-line treatment: CBIT (Comprehensive Behavioral Intervention for Tics) including HRT (Habit Reversal Training) — Level A evidence
  • First-line pharmacotherapy: α-2 agonists (guanfacine > clonidine) — especially when comorbid ADHD present; stimulants are NOT contraindicated in Tourette + ADHD despite the myth
  • Refractory tics: antipsychotics (aripiprazole, risperidone, pimozide—ECG for QTc, haloperidol), VMAT2 inhibitors (tetrabenazine), botulinum toxin for focal tics, DBS (CM thalamus or GPi) for severe adult-refractory cases in expert centers — not FDA-approved for Tourette in the US (off-label/investigational)
🔍 Buzzwords & Pathognomonic FindingsClinical · Comorbidity / mimic · Treatment
Clinical phenotype
  • Premonitory urge (“itch”/“pressure”) relieved by movementtic
  • Temporary voluntary suppressibility with rebound builduptic (vs chorea, myoclonus)
  • Waxing-waning + worse with stress, better with focused activityprimary tic disorder
  • ≥2 motor tics + ≥1 vocal tic, >1 year, onset <18Tourette syndrome (DSM-5)
  • Eye blinking as first tic in a young boyTourette (3–4:1 male predominance)
  • Coprolalia, echolalia, palilalia, echopraxia, copropraxiacomplex tics
Comorbidities / mimics
  • Abrupt prepubertal OCD/tics after sore throat + elevated ASO/anti-DNase BPANDAS
  • Same phenotype triggered by mycoplasma or viral infection (non-strep)PANS
  • Adolescent female, rapid-onset complex tics, no premonitory urge, TikTok exposurefunctional tic-like behavior
  • Fixed stereotyped pattern, distractible, female predominance, poor med responsefunctional tics
  • “Just right” symmetry/ordering compulsionsTourette-associated OCD (vs contamination-type primary OCD)
  • Tics + chorea + lip/tongue self-mutilation + acanthocytesneuroacanthocytosis
  • Juvenile-onset tics evolving with chorea + family historyHuntington disease
  • Adult-onset tics, no premonitory urge, no waxing/waningsecondary tics (stroke, TBI, encephalitis, drug-induced)
Treatment / pharmacology pearls
  • CBIT / HRT (awareness + competing response training)first-line behavioral therapy (Level A)
  • Guanfacine, clonidine (α-2 agonists)first-line pharmacotherapy, especially with comorbid ADHD
  • Aripiprazole, risperidone, haloperidol, pimozideantipsychotics for refractory tics (pimozide → QTc monitoring)
  • Tetrabenazine, deutetrabenazine, valbenazine (VMAT2 inhibitors)off-label severe tics (deutetra/valbenazine failed pediatric RCTs)
  • Topiramateadjunct with RCT support, weight-neutral option
  • Botulinum toxinfocal motor/vocal tics — may reduce premonitory urge too
  • DBS CM-Pf thalamus or GPisevere treatment-refractory adult Tourette in expert multidisciplinary centers; in the US it is not an FDA-approved Tourette indication and is generally off-label/investigational
  • SSRI + CBT for OCD; methylphenidate/stimulants for ADHDtreat comorbidities (stimulants generally tic-neutral — TACT trial)
Tic Classification

Definition & Key Features

  • Premonitory urge: uncomfortable sensory phenomenon preceding the tic (“itch” or “pressure”) — present in >90% of patients ≥10 years
  • Suppressibility: voluntarily suppressed for brief periods, but suppression builds urge (“rebound”)
  • Suggestibility: tics may increase when discussed or observed
  • Waxing and waning: severity fluctuates over weeks to months; types and locations change over time
  • Exacerbating: stress, fatigue, anxiety, excitement — Improving: focused concentration, sleep

Tic Types

CategoryDescriptionExamples
Simple MotorBrief, sudden, meaninglessEye blinking (most common initial tic), facial grimacing, head jerking, shoulder shrugging
Complex MotorCoordinated, purposeful-appearingTouching objects, jumping, squatting, copropraxia (obscene gestures), echopraxia (imitating movements)
Simple VocalMeaningless soundsSniffing, throat clearing, grunting, barking, coughing
Complex VocalLinguistically meaningfulCoprolalia (obscene words — ~10–15% of Tourette), echolalia (repeating others’ words), palilalia (repeating own words)

DSM-5 Tic Disorder Spectrum

  • Provisional tic disorder: Motor and/or vocal tics, duration <1 year, onset <18 years
  • Persistent (chronic) tic disorder: Motor OR vocal tics (not both), duration >1 year, onset <18 years
  • Tourette syndrome: Multiple motor tics + ≥1 vocal tic (not necessarily concurrent), duration >1 year, onset <18 years
💎 Board Pearl
  • Premonitory urge + suppressibility + waxing/waning = tics. The premonitory urge is the most distinguishing feature from other hyperkinetic movements.
  • Coprolalia occurs in ~10–15% of Tourette patients — NOT required for diagnosis.
  • Eye blinking is the most common initial tic. Motor tics typically precede vocal tics by 1–2 years.
Tourette Syndrome

Epidemiology & Genetics

  • Prevalence: ~1% of school-age children; male:female = 3–4:1
  • Age of onset: typically 4–6 years; peak severity: 10–12 years
  • Natural history: ~75–90% experience substantial reduction in tic severity by adulthood; ~1/3 achieve near/complete remission, ~1/3 have mild residual tics, ~1/3 have persistent moderate-to-severe tics
  • Genetics: Polygenic; MZ twin concordance 50–77%; SLITRK1 and HDC implicated in rare families

Pathophysiology

  • Cortico-striato-thalamo-cortical (CSTC) circuit dysfunction — disinhibition of motor and limbic circuits
  • Reduced caudate volume; dopamine hypothesis: hypersensitive striatal dopaminergic signaling — supported by response to D2 blockers

Diagnosis

  • Clinical diagnosis — no confirmatory lab or imaging required
  • DSM-5: Multiple motor + ≥1 vocal tic (need not be concurrent); >1 year duration; onset <18; not due to substance/medical condition
  • YGTSS (Yale Global Tic Severity Scale): Standardized rating of tic number, frequency, intensity, complexity, interference
Clinical Pearl
  • Motor and vocal tics do NOT need to occur simultaneously — both just need to have been present at some point during the illness.
  • Tic severity does not predict comorbidity severity — mild tics may coexist with severely disabling OCD or ADHD.
Comorbidities

Comorbidities are the rule rather than the exception and are often more disabling than the tics themselves.

ComorbidityPrevalenceKey Points
ADHD50–60%Most common; often appears before tics; stimulants generally safe; guanfacine treats both
OCD40–60%“Just right” phenomena, symmetry, ordering > contamination; SSRIs + CBT first-line; may persist after tics remit
Anxiety30–40%Generalized, social, separation anxiety; exacerbates tics
Depression20–25%Primary or secondary to social stigma and functional impairment
Learning disabilities20–30%Often related to comorbid ADHD/executive dysfunction rather than tics per se
Rage attacks25–70%Explosive outbursts disproportionate to trigger; overlaps with ADHD impulsivity
💎 Board Pearl
  • Treat the most disabling condition first — often ADHD or OCD rather than tics.
  • Stimulants are NOT contraindicated in Tourette — methylphenidate may mildly/transiently worsen tics but is generally safe.
  • “Just right” OCD (symmetry, ordering) is more characteristic of Tourette-associated OCD than contamination-type.
Treatment

General Principles

  • Not all tics require treatment — treat only if functionally impairing, painful, or causing significant distress
  • Psychoeducation: Reassure about waxing/waning nature and likelihood of improvement with age

Behavioral Therapy (First-Line)

  • CBIT (Comprehensive Behavioral Intervention for Tics): Gold-standard; includes HRT + function-based interventions + relaxation
  • HRT (Habit Reversal Training): Awareness training (recognize premonitory urge) + competing response training (incompatible voluntary action)
  • Level A evidence; comparable efficacy to medications without side effects; effective in children ≥9 years and adults

Pharmacotherapy

TierDrug ClassAgentsKey Points
First-lineAlpha-2 agonistsGuanfacine, clonidineGuanfacine preferred (less sedation); also treats ADHD; SE: sedation, hypotension
Second-lineTypical antipsychoticsHaloperidol (FDA-approved), pimozide (FDA-approved), fluphenazine (off-label)Most potent tic suppressors; pimozide → QTc prolongation (ECG monitoring); fluphenazine sometimes preferred over haloperidol/pimozide due to lower reported EPS in observational data
Atypical antipsychoticsAripiprazole (FDA-approved 2014, pediatric), risperidone (off-label)Aripiprazole increasingly preferred (partial D2 agonist, favorable profile)
AdjunctsOtherTopiramate (off-label), tetrabenazine (off-label)Topiramate has RCT support; tetrabenazine off-label for severe tics (risk of depression); deutetrabenazine (ARTISTS-1/2) and valbenazine failed to meet primary endpoints in pediatric Tourette RCTs — neither FDA-approved for tics
Focal ticsBotulinum toxinOnabotulinumtoxinAFocal motor or vocal tics; may reduce both the tic and premonitory urge in some patients; repeat q3–4 months
RefractoryDeep brain stimulationCM-Pf thalamus (predominant modern target), GPiConsider only for severe, treatment-refractory adult Tourette syndrome in expert multidisciplinary centers; ESTEL trial supports CM-Pf efficacy; in the US, DBS is NOT an FDA-approved Tourette indication and is generally off-label/investigational (FDA HDEs exist for OCD and historically dystonia, not Tourette)
💎 Board Pearl
  • CBIT/HRT is first-line for tics (Level A evidence). Always offer behavioral therapy before or alongside medications.
  • Alpha-2 agonists (guanfacine > clonidine) are first-line pharmacotherapy — especially when comorbid ADHD is present.
  • Pimozide requires ECG monitoring for QTc prolongation — contraindicated with CYP3A4 inhibitors.
  • Botulinum toxin may reduce both the tic and premonitory urge in some patients — potential dual benefit for focal tics.
  • TACT trial (Tourette Syndrome Study Group, Neurology 2002) — methylphenidate + clonidine combination effective and tic-neutral in children with tics + ADHD.
Secondary Tics

PANDAS / PANS

  • PANDAS: Abrupt onset of OCD and/or tics following Group A strep; prepubertal; episodic course with strep-linked exacerbations; proposed mechanism involves molecular mimicry with anti–basal ganglia/anti-neuronal antibodies, though specific antibodies remain unvalidated and PANDAS as a distinct entity remains controversial
  • PANS: Broader category — same phenotype, not limited to strep trigger (mycoplasma, viral, other immune)
  • Treatment: Antibiotics for strep (prophylaxis debated); IVIG/plasmapheresis studied in severe cases with mixed/inconclusive RCT evidence (Williams 2016 IVIG trial negative for primary endpoint); standard tic/OCD medications

Drug-Induced Tics

  • Stimulants: Methylphenidate, amphetamines — may unmask pre-existing tic tendency
  • Cocaine, methamphetamine: Dopaminergic excess → tics and stereotypies
  • Withdrawal tics: Sudden cessation of dopamine blockers (neuroleptic withdrawal-emergent tics)

Structural & Neurodegenerative

  • Stroke or TBI involving basal ganglia or frontal cortex
  • Huntington disease: Tics may be early feature, especially juvenile-onset HD
  • Neuroacanthocytosis: Tics + chorea + lip/tongue biting; acanthocytes on smear
  • Encephalitis: Post-encephalitic tics (viral, autoimmune including anti-NMDAR)
Clinical Pearl
  • Abrupt explosive onset of tics + OCD in a prepubertal child after sore throat → PANDAS. Check ASO, anti-DNase B, throat culture.
  • Consider secondary causes when tics are atypical: adult onset, sudden onset, no premonitory urge, associated neuro signs, or no waxing/waning.
Functional (Psychogenic) Tics

Rapid-onset functional tic-like behaviors surged 2020–2022, frequently associated with social media exposure (TikTok); predominantly adolescent females.

FeaturePrimary Tics (Tourette)Functional Tic-Like Behaviors
OnsetGradual, childhood (4–6 yr)Abrupt, often adolescent/young adult
Premonitory urgePresent (>90%)Typically absent
SuppressibilityTemporarily suppressibleNo consistent suppressibility
PatternWaxes/wanes; type changesFixed, repetitive, stereotyped
DistractionTics may persistOften resolve with distraction
GenderMale predominance (3–4:1)Female predominance
Coprolalia~10–15%Frequently present; complex phrases
Response to tic medsYesPoor or absent

Management

  • Positive diagnosis based on functional features — not a diagnosis of exclusion
  • Treatment: Psychoeducation, CBT, physical therapy with motor retraining; avoid unnecessary dopamine blockers
💎 Board Pearl
  • No premonitory urge + abrupt onset + fixed pattern + female predominance + distractibility = functional tic-like behavior.
  • Functional tics do NOT respond to tic medications — dopamine blockers should be avoided.

References

  • Robertson MM, Eapen V, Singer HS, et al. Gilles de la Tourette syndrome. Nat Rev Dis Primers. 2017;3:16097.
  • Pringsheim T, Okun MS, Müller-Vahl K, et al. Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019;92(19):896-906.
  • Piacentini J, Woods DW, Scahill L, et al. Behavior therapy for children with Tourette disorder: a randomized controlled trial. JAMA. 2010;303(19):1929-1937.
  • Leckman JF, Zhang H, Vitale A, et al. Course of tic severity in Tourette syndrome: the first two decades. Pediatrics. 1998;102(1):14-19.
  • Swedo SE, Leonard HL, Garvey M, et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. Am J Psychiatry. 1998;155(2):264-271.
  • Pringsheim T, Holler-Managan Y, Okun MS, et al. Comprehensive systematic review summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019;92(19):907-915.
  • Müller-Vahl KR, Sambrani T, Jakubovski E. Tic disorders revisited: introduction of the term “functional tic-like behaviors.” Mov Disord Clin Pract. 2022;9(8):1076-1084.
  • Martino D, Pringsheim TM. Tourette syndrome and other chronic tic disorders: an update on clinical management. Expert Rev Neurother. 2018;18(2):125-137.
🔒

Continue reading — sign in

The full note has more clinical pearls, tables, and board-focused tips. Free account, no fee.